Analyst Ratings For NASDAQ:CNCE – Concert Pharmaceuticals (NASDAQ:CNCE)
Today, HC Wainwright reiterated its Buy rating on NASDAQ:CNCE – Concert Pharmaceuticals (NASDAQ:CNCE) with a price target of $26.00.
Some recent analyst ratings include
- 5/4/2018-HC Wainwright Reiterated Rating of Buy .
- 4/10/2018-Mizuho Reiterated Rating of Buy.
- 1/12/2018-Stifel Nicolaus Reiterated Rating of Buy.
- 6/12/2017-Aegis Reiterated Rating of Buy.
- 9/7/2016-Brean Capital Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:CNCE – Concert Pharmaceuticals (NASDAQ:CNCE)
NASDAQ:CNCE – Concert Pharmaceuticals (NASDAQ:CNCE) has insider ownership of 10.10% and institutional ownership of 72.73%.
- On 4/17/2018 James V Cassella, Insider, sold 10,582 with an average share price of $20.18 per share and the total transaction amounting to $213,544.76.
- On 2/1/2018 Richard Aldrich, Director, sold 11,946 with an average share price of $20.89 per share and the total transaction amounting to $249,551.94.
- On 1/29/2018 Richard Aldrich, Director, sold 18,054 with an average share price of $20.63 per share and the total transaction amounting to $372,454.02.
- On 1/26/2018 Richard Aldrich, Director, sold 5,000 with an average share price of $20.46 per share and the total transaction amounting to $102,300.00.
- On 1/24/2018 Richard Aldrich, Director, sold 30,000 with an average share price of $19.68 per share and the total transaction amounting to $590,400.00.
- On 1/22/2018 Richard Aldrich, Director, sold 10,000 with an average share price of $19.55 per share and the total transaction amounting to $195,500.00.
- On 1/19/2018 Richard Aldrich, Director, sold 30,000 with an average share price of $19.35 per share and the total transaction amounting to $580,500.00.
Recent Trading Activity for NASDAQ:CNCE – Concert Pharmaceuticals (NASDAQ:CNCE)
Shares of NASDAQ:CNCE – Concert Pharmaceuticals closed the previous trading session at 20.26 up +0.57 2.92% with 19.8799991607666 shares trading hands.